4 forms: scored tablet. In force in Georgia: 4 of 4 (veterinary register).
Forms and doses4 of 4 in force in Georgia
The dose from the product's label, by species and weight. Check the label of the pack you use.
Form
Species
Weight
Dose
Frequency
Georgia
Scored tablet · Dog 4.4–6 kg
Dog
4.4–6 kg
1 tablet
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
4.4–6 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
3–4.3 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
6.1–9 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
9.1–13.5 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
19.4–26.5 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
13.6–19.3 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
26.6–39.5 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
39.6–54 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
The label table delivers 0.8-1.2 mg atinvicitinib/kg once daily. Tablets can be divided only into equal halves. Safety has not been established in dogs under 6 months or below 3 kg. Investigate and treat complicating infection, parasites and underlying allergy; use with immune suppression or progressive malignancy only after veterinary benefit-risk assessment. Pregnancy, lactation and breeding use are not recommended. Common adverse events include vomiting, diarrhoea, lethargy and anorexia.
Dog
54.1–79 kg
By mouth
once daily, at or around feeding
EMA SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Numelvi 4.8 mg, 7.2 mg, 21.6 mg and 31.6 mg tablets for dogs - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.
For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.
Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.
The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.
